Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025
Relay Therapeutics (NASDAQ: RLAY), a clinical-stage precision medicine company, announced it will release its fourth quarter and full year 2024 financial results and corporate highlights on Wednesday, February 26, 2025, after U.S. market close. The company specializes in combining computational and experimental technologies for drug discovery.
Relay Therapeutics (NASDAQ: RLAY), un'azienda di medicina di precisione in fase clinica, ha annunciato che rilascerà i suoi risultati finanziari del quarto trimestre e dell'intero anno 2024 e i punti salienti aziendali il mercoledì 26 febbraio 2025, dopo la chiusura del mercato statunitense. L'azienda si specializza nella combinazione di tecnologie computazionali ed experimental per la scoperta di farmaci.
Relay Therapeutics (NASDAQ: RLAY), una empresa de medicina de precisión en etapa clínica, anunció que publicará sus resultados financieros del cuarto trimestre y del año completo 2024 y los aspectos destacados corporativos el miércoles 26 de febrero de 2025, después del cierre del mercado estadounidense. La empresa se especializa en combinar tecnologías computacionales y experimentales para el descubrimiento de fármacos.
Relay Therapeutics (NASDAQ: RLAY), 임상 단계의 정밀 의학 회사,는 2024년 4분기 및 전체 연도 재무 결과와 기업 하이라이트를 2025년 2월 26일 수요일에 미국 시장 마감 후 발표할 것이라고 발표했습니다. 이 회사는 약물 발견을 위해 컴퓨터 및 실험 기술을 결합하는 데 전문화되어 있습니다.
Relay Therapeutics (NASDAQ: RLAY), une entreprise de médecine de précision en phase clinique, a annoncé qu'elle publiera ses résultats financiers du quatrième trimestre et de l'année complète 2024 ainsi que les points forts de l'entreprise le mercredi 26 février 2025, après la fermeture du marché américain. L'entreprise se spécialise dans la combinaison de technologies informatiques et expérimentales pour la découverte de médicaments.
Relay Therapeutics (NASDAQ: RLAY), ein Unternehmen für präzisionsmedizinische Forschung in der klinischen Phase, gab bekannt, dass es seine finanziellen Ergebnisse für das vierte Quartal und das gesamte Jahr 2024 sowie Unternehmenshighlights am Mittwoch, den 26. Februar 2025, nach Börsenschluss in den USA veröffentlichen wird. Das Unternehmen spezialisiert sich auf die Kombination von rechnergestützten und experimentellen Technologien zur Medikamentenentdeckung.
- None.
- None.
CAMBRIDGE, Mass., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report fourth quarter and full year 2024 financial results and corporate highlights after the U.S. financial markets close on Wednesday, February 26, 2025.
About Relay Therapeutics
Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of complementary techniques and technologies, Relay Therapeutics aims to push the boundaries of what’s possible in drug discovery. Its Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics’ initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit www.relaytx.com or follow us on Twitter.
Contact:
Pete Rahmer
prahmer@relaytx.com
Media:
Dan Budwick
1AB
973-271-6085
dan@1abmedia.com
FAQ
When will Relay Therapeutics (RLAY) release Q4 2024 earnings?
What period will Relay Therapeutics' (RLAY) upcoming earnings report cover?
Will Relay Therapeutics (RLAY) include corporate highlights in their Q4 2024 report?
What time will RLAY release their Q4 2024 earnings report?
